Moolec Science

Moolec Science is a UK-based startup developing affordable alternative proteins using molecular farming technology and is a spinout of Argentina-based bioscience conglomerate Bioceres SA. The company uses plants as bioreactors to produce animal protein expressions by embedding animal protein genes into plants, offering a sustainable and cost-effective alternative to traditional animal farming.

In 2008, Moolec Science produced the world’s first bovine chymosin protein in safflower on an industrial scale and developed a platform around its patented technology, called SPC. The company plans on developing other animal proteins, such as porcine, using soybeans and peas to formulate sustainable meat alternative hybrids. In July 2023 , the company developed Piggy Sooy, a molecular farming platform, that claims to deliver four times more pork protein expression from soy seeds than previously estimated.

In April 2023 , Moolec acquired ValoraSoy, a company focused on producing and commercializing functional soy proteins for USD 6 million. The company paid  ~USD 2.5 million in cash, and the rest with its shares in three years based on vesting and business metrics. The acquisition is expected to help Moolec accelerate its growth in the food ingredients industry by expanding its commercial network and complementing its Molecular Farming Platform.

Key customers and partnerships

In August 2021, Moolec Science entered into a partnership with Grupo Insud, a producer of biosimilars and other active ingredients for the Pharmaceutical Industry to research and develop yeast, fungi, and other microorganisms-based ingredients that complement Moolec’s product

Funding and Financials

In June 2022 , the company entered into a definitive business combination agreement with Special Purpose Acquisition Company (SPAC) Light Jump Acquisition, valuing the combined company at a pro forma equity value of USD 504 million. Following the successful completion of the combination, in January 2023 Moolec Science began trading ordinary shares and warrants on NASDAQ under ticker symbols MLEC and MLECW respectively. Proceeds from the transaction were planned to be utilized for R&D, acquiring regulatory approvals, and expediting commercialization.